CA2215046A1 - Pharmaceutical, cosmetic and/or food composition having anti-oxidant properties - Google Patents
Pharmaceutical, cosmetic and/or food composition having anti-oxidant properties Download PDFInfo
- Publication number
- CA2215046A1 CA2215046A1 CA002215046A CA2215046A CA2215046A1 CA 2215046 A1 CA2215046 A1 CA 2215046A1 CA 002215046 A CA002215046 A CA 002215046A CA 2215046 A CA2215046 A CA 2215046A CA 2215046 A1 CA2215046 A1 CA 2215046A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical
- cosmetic
- composition according
- sic
- pyrazyn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 235000013305 food Nutrition 0.000 title claims abstract description 33
- 239000002537 cosmetic Substances 0.000 title claims abstract description 32
- 230000003078 antioxidant effect Effects 0.000 title abstract description 14
- 239000002243 precursor Substances 0.000 claims abstract description 6
- 150000003216 pyrazines Chemical class 0.000 claims abstract description 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 230000007170 pathology Effects 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000003244 pro-oxidative effect Effects 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229910052711 selenium Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 229910052714 tellurium Inorganic materials 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000000711 cancerogenic effect Effects 0.000 claims description 3
- 231100000315 carcinogenic Toxicity 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229910006069 SO3H Inorganic materials 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 abstract description 7
- 235000006708 antioxidants Nutrition 0.000 abstract description 6
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 44
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyrazine Chemical compound C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 description 25
- 102000019197 Superoxide Dismutase Human genes 0.000 description 22
- 108010012715 Superoxide dismutase Proteins 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 229940032362 superoxide dismutase Drugs 0.000 description 8
- 239000012071 phase Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 229910052785 arsenic Inorganic materials 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical class C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003217 anti-cancerogenic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 230000006364 cellular survival Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000021092 sugar substitutes Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- -1 coated oruncoated Substances 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910017518 Cu Zn Inorganic materials 0.000 description 1
- 229910017752 Cu-Zn Inorganic materials 0.000 description 1
- 229910017943 Cu—Zn Inorganic materials 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000009133 cooperative interaction Effects 0.000 description 1
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical group [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
A pharmaceutical, cosmetic and/or food composition including a pyrazine derivative of formula (I) or (II), and/or a precursor thereof of formula (III), and the use thereof as an anti-oxidant, are disclosed.
Description
CA 0221~046 1997-09-09 WO 96/28160 - l - PCT/BE96/00024 PHARMACEUTICAL, COSMETIC AND/OR FOOD COMPOSITION ~AVING
ANTIOXIDANT PROPERTIES.
Subject of the invention.
The present invention relates to a pharma-ceutical, cosmetic and/or food composition intended especially for the prevention and/or treatment of pathologies associated with prooxidant agents.
The present invention also relates to the use of the pharmaceutical, cosmetic and/or food composition according to the invention.
Technological ~round and prior art underlying the in~ention.
Coelenterazine, imidazolopyrazine, constitutes the substrate o~ bioluminescent reactions in many marine organisms.
In these organisms, the oxidation of coelen-terazine by molecular oxygen, a reaction catalyzed by an enzyme (luciferase), is responsible for the light-emitting reaction. Studies have demonstrated thepresence of coelenterazine in many non-bioluminescent organisms (Schimomura, Comp. Biochem. Physiol. 86B, pp. 361-363 (1987)).
The synthesis o~ imidazolopyrazine is known to a person skilled in the art from the ~ollowing documents: Inoue et al., Chemistry Letters, pp. 299-300 (1980); Tiranishi and Goto, Bulletin Ot Chemical Society Japanese 63, pp. 3132-3140 (1990); Qi et al., Journal of Chemical Society Perkin Trans 1, pp. 1607-1611 (1982); Mc Capra and Roth, Journal of Chemical Society Chemistry Community, pp. 894-895 (1972); Inoue et al., Chemistry Letters, pp. 141-144 (1975); Inoue et al., Tetrahedron Letters No. 31, pp. 2685-2688 (1977);
Qi et al. Journal o~ Chemical Society Chemistry Commu-nity, pp. 1307-1309 (1991); Hori et al., Biochemistry, Vol. 12 No. 22, pp. 4463-4468 (1973); Hart et al., Biochemical and Biophysical Research Communication, pp. 980-986, (1978) CA 0221~046 1997-09-09 However, none of these documents describes a pharmaceutical, cosmetic or food composition comprising one of these imidazolopyrazine derivatives, or the antioxidant properties of these products, or any other S therapeutic application of these products.
Antioxidant molecules such as vitamins, for instance vitamin E (fat-soluble) or cysteine derivatives (water-soluble), are also used already in cosmetic, pharmaceutical and/or food ;applications. However, these antioxidant molecules have the drawback either of not being water-soluble, or of having an excessively high toxicity as well as an excessively low efficacy.
Objectives of the invention.
The present invention is directed towards obtaining a new pharmaceutical, cosmetic and/or food composition advantageQusly permitting the prevention and/or treatment of pathologies associated with prooxi-dant agents, and especially a pharmaceutical, cosmetic and/or food composition having anti-inflammatory and/or anticarcinogenic properties.
An additional objective of the present inven-tion is to obtain said pharmaceutical, cosmetic and/or food compositions which shall be characterized by a low toxicity or an absence of toxicity, by a high solubi-lity in a large number of solvents (H2O, alcohols, etc.)and/or lipids and/or by a high stability, especially at acid pH.
Characteristic ~eatures o~ the present invention.
The present invention relates to a pharmaceu-tical, cosmetic and/or food composition comprising apyrazine derivative of formula .B-- R 2 .~ j=<
~1 ~,~ or ~l ~ ~ ~
Nff R R ~ ~ l R4 CA 0221~046 1997-09-09 and/or its precursor of formula R3 C~2H B ~2 ~ R4 P ~
C~2--C~--~--C--C~--K~--C--C~--N~2 in which formulae B is a radical chosen from the group consisting of X, X-SO3H, X-PO4, X-alkyl=O, the said alkyl consisting of 1 to 20 carbon atoms optionally comprising 1 to 10 hetero atoms and in which the carbon atoms can be optionally substituted with any element of the Mendeleev table, preferably an element chosen from the group consisting of H, B, N, O, F, ~, S, Cl, As, Se, Br, Te and I, X being an element chosen from the group con-sisting of O, S, Se and Te;
R1, R2, R3 and R4 are H, radicals chosen from the group consisting of alkyl, alkenyl, alkynyl, aryl, aryl-alkyl, alkylaryl, heteroaryl, heteroalkyl and hetero(alkylaryl and arylalkyl), preferably con-sisting of 1 to 20 carbon atoms optionally comprising 1 to 10 hetero atoms and in which the carbon atoms can be optionally substituted with any element o~ the Mendeleev table, preferably an element chosen from the group consisting of H, B, N, O, F, P, S, Cl, As, Se, Br, Te and I, or chains of formula (Rs x R6) n, where n 2 1, x represents one or more hetero atoms and R5 and R6 are radicals chosen from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkylaryl, heteroaryl, heteroalkyl and hetero(alkylaryl and arylalkyl), consisting of 1 to 20 carbon atoms optionally comprising 1 to 10 hetero atoms and in which the carbon atoms can be optionally substituted with any element of the Mendeleev table, preferably an element chosen from the group consisting of H, B, N, O, F, P, S, Cl, As, Se, Br, Te and Ii and optionally an appropriate pharmaceutical, cosmetic and/or food vehicle.
CA 0221~046 1997-09-09 ~referably, in the pyrazine derivatives according to the invention, Rl is H, R2 and R4 are aryl or alkylaryl groups, preferably consisting of 1 to 20 carbon atoms optionally comprising 1 to 10 hetero atoms and in which the carbon atoms can be optionally substituted with any element of the Mendeleev table, preferably an element chosen from the group consisting of H, B, N, O, F, P, S, Cl, As, Se, Br, Te and I, R3 represents a phenoL group or a chain of formula (R5 X R6) n in which n = 1, x represents O, R5 iS a phenyl, and .
R6 is a methyl ~referably, the pyrazine derivative of the pharmaceutical, cosmetic and/or food composition according to the invention is chosen from the group consisting of:
* 3,7-dihydro-2-(p-hydroxybenzyl)-6-(p-hydroxyphenyl)-8-benzylimidazo[1,2-a]pyrazyn-3-one [sic] (CLZN) * 3,7-dihydro-2-methyl-6-(p-metoxyphenyl)-8-benzyl-imidazo[l,2-a]pyrazyn-3-one [sic] (CLZN-7) * 3,7-dihydro-2-phenyl-6-(p-metoxyphenyl)-8-benzyl-imidazo[l,2-a]pyrazyn-3-one [sic] (CLZN-8) * 3,7-dihydro-2-methyl-6-(p-hydroxyphenyl)-8-benzyl-imidazo[l,2-a]pyrazyn-3-one [sic] (CLZN-9) * 3,7-dihydro-2-phenyl-6-(p-hydroxyphenyl)-8-benzyl-imidazo[l,2-a]pyrazyn-3-one [sic] (CLZN-10) * 3,7-dihydro-2-benzyl-6-(p-hydroxyphenyl)-8-benzyl-imidazo[l,2-a]pyrazyn-3-one [sic] (CLZN-ll) and optionally an appropriate pharmaceutical, cosmetic and/or food vehicle.
Another aspect of the present invention relates to the use of the composition according to the invention for the binding of prooxidant agents (free radicals) such as peroxides, superoxides, etc.
The present invention also relates to a method CA 0221~046 1997-09-09 of treatment and/or prevention of pathologies associated with the action of prooxidant agents, especially inflammatory or carcinogenic pathologies, in which the pharmaceutical, cosmetic and/or food composi-tion according to the present invention is administeredto a patient.
The pharmaceutical, cosmetic and/or food vehicles according to the invention are vehicles which are appropriate, in parti~ular, for oral administra-tion, for example in the form of lozenges, coated oruncoated, pills, capsules, solutions, essential oils and/or syrups.
Other appropriate pharmaceutical, cosmetic and/or food vehicles can be used, depending on the chosen mode of administration.
In particular,_ these pharmaceutical, cosmetic and/or food vehicles can be creams or sun oils which are well known to a person skilled in the art, which can coat various parts of the human or animal body in combination with other skin-protecting agents.
In addition, the products of the invention can be readily incorporated in solvents (aqueous media, alcohols, etc.) or lipids (for example in combination with food oils or suntan oils).
The pharmaceutical, cosmetic and/or food compositions according to the invention are prepared according to processes generally used by a person skilled in the art, especially by pharmacists, and can comprise any vehicle or any adjuvant which is pharma-ceutically appropriate, solid or liquid, and non-toxic.
The incorporation of the derivatives according to the invention in a pharmaceutical formulation medium can also be envisaged.
The percentage of active product (pyrazine derivatives) in the pharmaceutical vehicle can vary over very wide ranges, limited only by the tolerance and level of acceptance of the product by the patient.
The limits are generally determined by the frequency of administra~ion to the patient.
CA 0221~046 1997-09-09 A final aspect of the present invention relates to the use of the composition according to the invention for the preparation of a medicament intended for the prevention and/or treatment of pathologies associated with the action of peroxidant agents.
In particular, the present invention relates to the use of the composition according to the invention for the preparation of a medicament intended for the prevention and/or treatment" of inflammatory or carcino-genic pathologies and/or for the treatment of cancerous tumours.
Brief description of the figures.
Figure 1 depicts the structure of the imidazolo-pyrazine derivatives used in the pharma-ceutical and food composition according to the invention.
Figure 2 depicts the relationship linking the super-oxide dismutase (SOD) concentration and the ratio of the intensities measured in the absence and in the presence of superoxide dismutase (Io/I) for two coelenterazine (CLZN) concentrations. In this figure, the results of the same experiment carried out when the superoxide dismutase is heat-denatured are also presented.
Figure 3 depicts the change in the slope of the relationship linking the superoxide dismutase concentration and Io/I and in the rate con-stant KSOD as a function of the coelenterazine concentration.
Figure 4 depicts the linear relationship between the coelenterazine concentration and the maximum intensity of the luminescence brought about by the superoxide anion under our experi-mental conditions.
Figure 5 depicts the inactivation of superoxide dismutase by 10-2 M KCN. The enzyme activity is completely inhibited by KCN, and no observable difference remains between the two CA 022l~046 l997-09-09 coelenterazine concentrations ( 10-7 and 4 10-7 M) Figure 6 depicts the influence of the luminol concen-tration on the slope of the relationship linking the superoxide dismutase concentra-tion and the ratio of the intensities Io/I.
Figure 7 depicts the stability of the derivative 10 in an aqueous medium. Three 10-5 M solutions of CLZN-10 were prepared in citrate (pH 4), phosphate (pH 7) and glycine (pH 10) buffers.
Aliquots of these solutions were sampled regularly and the CLZN-10 assayed by lumi-nescence in DMSO.
Figures 8 and 9 depict the percentage cellular survival of human fibroblasts subjected to an oxida-tive stress inducer in the presence of increasing doses of derivatives according to the invention, with (Figure 9) or without (Figure 8) serum.
Figure 10 depicts diagrammatically the conversion of a precursor of the derivative according to the invention to a derivative of the invention.
Figure 11 depicts the percentage survival of different cell types as a function of increasing doses of CLZ-9 (M).
EXAMPLES.
1. Origin of the antioxidant properties of the pharma-ceutical, cosmetic and food composition according to the invention.
The antioxidant properties of imidazolopyrazine derivatives appear to result, on the one hand from the properties of these molecules to react very rapidly with the activated forms of oxygen.
This property could be due to the existence of electron donor (carbonyl) and electron acceptor (nitro-gen) groups in the central nucleus of the molecule.
The phenol groups present in the molecules could also constitute (ROS) scavengers.
CA 022l~046 lss7-os-os The main reaction mechanism is considered to be comparable to the one involved in the chemoluminescent oxidation of coelenterazine by molecular oxygen.
On the other hand, these properties might result from the very high instability of the excited product formed during the reaction of ROSs with imidazolopyrazines.
In effect, contrary to other known substances displaying antioxidant activity, the reaction product is not a stable and unreactive radical. On the contrary, the excited product formed is considered to be characterized by a very great instability. The latter is such that these products appear to disintegrate instantaneously by rupture of the imidazolopyrazine nucleusi a part of the destructive energy of the ROSs is_dissipated in the form of light, while the remainder is liberated in the form of thermal radiation.
The results below indicate the existence of a positive cooperative interaction between the imidazolo-pyrazines and the cytosolic superoxide dismutase (Cu-Zn form) of cells.
This behaviour is demonstrated in experiments that enable the reactivity of imidazolopyrazines with the superoxide anion to be measured. This method is based on the capacity of imidazolopyrazines to react with the superoxide anion, emitting light.
In these experiments, a constant level of superoxide anion is generated by an enzymatic method, by reacting xanthine oxidase with hypoxanthine in the presence of oxygen. This reaction is carried out in the presence of increasing concentrations of superoxide dismutase (Cu-Zn superoxide dismutase), which will compete with the imidazolopyrazine for the superoxide anion and hence modify the maximum light intensity produced.
The maximum light intensity, measured by a luminometer during the competltion reaction, is linked to the ratio in [sic] imidazolopyrazine and superoxide CA 0221~046 1997-os-os _ g _ dismutase concentrations, as well as to that of the respective rate constants.
Consequently, knowing the rate constant of the reaction of the competing antioxidant with the super-oxide anion (K3), the rate constant of the reaction ofthe imidazolopyrazine with the superoxide anion (K2) may be calculated:
Io = light intensity observed in the absence of the competitor I = light intensity observed in the presence of the competitor SOD = superoxide dismutase IMPZ = imidazolopyrazine . IMPZ
~ /I = 1 +{K3 / (Kl [~2] - K2t ~ ])}[SOD] (1) 2 ~7 =' ~2 f ~, K~
IMPZ + O~ =~ . + h~ (2) - amidopyraz1ne SOD + 2 07 =~ ~7 + o 2- + SOD (3) By carrying out this experiment at two imidazolopyrazine concentrations, it is possible to eliminate K1 [o22~] corresponding to the spontaneous disproportionation reaction of o22~. The slopes A and B
of the straight lines linking Io/I [sic] to the super-oxide dismutase concentration are:
1st concentration A = K3 / (Kl [~2 ] + K2 [IMPZ]l) of IMPZ
and 2nd concentration A = K3 / (K [07] + K7 [IMPZ]l) of IMPZ
and then K~ = K3 / ( ~IMPZ]l -- [IMPZ]7) / (1 / A) -- 1 / B) CA 0221~046 1997-09-09 When the imidazolopyrazine concentration is increased, the slope of the relationship linking Io/I
[sic] to the superoxide dismutase concentration should decrease.
These experiments revealed a reverse behaviour, that is to say a rise in the slope for higher imidazolo-pyrazine concentrations (Figure 2). This demonstrates a linear relationship between the coelenterazine concen-tration and the slope of the straight line (Figure 3).
This rise in slope may be interpreted as an increase in the apparent rate constant of the superoxide dismutase.
Thus, when the coelenterazine concentration is multiplied by 8 (from 50 to 400 nM), the rate constant KSOD rises from 2 x 109 to 2.5 x 101~, equivalent to a 12.5_fold increase. This effect was observed for two other imidazolopyrazines tested (CLZN-9 and -10). The magnitude of the increase in KSOD appears to be achieved in proportions similar to those of coelenterazine.
Various controls were carried out in order to verify that the results are not due to an artefact.
These include:
- a test of linearity between the imidazolopyrazine concentration and the measured light intensity (Figure 4);
- heat denaturation of the superoxide dismutase used shows that the reduction in magnitude of light production on reacting the imidazolopyrazines with the superoxide anion does indeed result from an enzyme activity and not from the presence of metallic contaminants (Figure 2);
- the inactivation of superoxide dismutase by cyanide confirms that the enzyme activity does indeed correspond to superoxide dismutase and not to a protein contaminating the commercial sample (Figure 5);
- lastly, identical experiments were carried out with luminol, a chemoluminescent molecule that reacts with the superoxide anion, which revealed a behaviour of this product in accordance with CA 0221~046 1997-09-09 theoretical predictions, that is to say a regular decrease in the slope when the luminol concentra-tion is increased (Figure 6).
Consequently, the antioxldant and consequently anticarcinogenic properties of a pharmaceutical, cosmetic or food composition comprising imidazolo-pyrazine derivatives are completely unexpected, since the binding of superoxide dismutase by the imidazolo-pyrazine derivatives of the composition according to the invention is specific and is not observed with other chemoluminescent molecules such as luminol.
In view of the importance of superoxide dis-mutase in combating oxidative stress (see Fridovitch I, Journal of Biological Chemistry 264 (1989), pp. 7761-7764), the action of the imidazolopyrazine derivativeson this enzyme would strengthen the antioxidative defences of the cells, endowing them as a result with better protection against prooxidant agents.
2 0 2 . In vi tro toxi ci ty .
The low toxicity of the pharmaceutical, cosmetic or food composition of the invention for human cells is demonstrated in the experiments which follow.
Each of the imidazolopyrazine derivatives tested was applied to human fibroblasts (MRC5) in culture. The doses of the compounds ranged from 10-8 to 10-4 M. These compounds were applied 48 hours after the cells were inoculated into wells (volume = 150 ,ul; 3000 cells per well).
After a further 24 hour period, the culture medium is renewed, the cells are incubated for 72 hours and their level of survival and of growth is evaluated by measuring the total protein contents in each well (Biorad). The results show that the imidazolopyrazine derivatives have little or no toxicity for these cells.
Only the derivative CLZN-11 displays a significant toxicity for a concentratlon of 0.1 mM.
However, the slight toxicity of these deriva-tives at a concentration of 10-4 M is explained by the CA 0221~046 1997-09-09 negative action of the 1~ ethanol used to solubilize these derivatives. Neither of the two degradation products of the derivatives (CLMN-4 and -5) is toxic for the cells.
In comparison with coelenterazine, derivatives comprising additional phenyl groups display better stability. While the stability of coelenterazine is only a few hours in an aqueous medium and irrespective of the pH, the products derived from it display excellent stability at acid and neutral pH, while their half-life is in the region of 60 minutes at alkaline pH
(Figure 7).
Similar in vitro toxicity tests were performed on other m~mm~lian (porcine, human, etc.) cell types.
Figure 11 depicts the percentage survival of different cell types ~fibroblasts, human (ECV) or pig (EAP) endothelial cells) as a function of increasing doses of CLZ-9 (molar). A toxic effect of the products can possibly be observed on a certain cell type at high concentrations (10-4 M in pigs).
ANTIOXIDANT PROPERTIES.
Subject of the invention.
The present invention relates to a pharma-ceutical, cosmetic and/or food composition intended especially for the prevention and/or treatment of pathologies associated with prooxidant agents.
The present invention also relates to the use of the pharmaceutical, cosmetic and/or food composition according to the invention.
Technological ~round and prior art underlying the in~ention.
Coelenterazine, imidazolopyrazine, constitutes the substrate o~ bioluminescent reactions in many marine organisms.
In these organisms, the oxidation of coelen-terazine by molecular oxygen, a reaction catalyzed by an enzyme (luciferase), is responsible for the light-emitting reaction. Studies have demonstrated thepresence of coelenterazine in many non-bioluminescent organisms (Schimomura, Comp. Biochem. Physiol. 86B, pp. 361-363 (1987)).
The synthesis o~ imidazolopyrazine is known to a person skilled in the art from the ~ollowing documents: Inoue et al., Chemistry Letters, pp. 299-300 (1980); Tiranishi and Goto, Bulletin Ot Chemical Society Japanese 63, pp. 3132-3140 (1990); Qi et al., Journal of Chemical Society Perkin Trans 1, pp. 1607-1611 (1982); Mc Capra and Roth, Journal of Chemical Society Chemistry Community, pp. 894-895 (1972); Inoue et al., Chemistry Letters, pp. 141-144 (1975); Inoue et al., Tetrahedron Letters No. 31, pp. 2685-2688 (1977);
Qi et al. Journal o~ Chemical Society Chemistry Commu-nity, pp. 1307-1309 (1991); Hori et al., Biochemistry, Vol. 12 No. 22, pp. 4463-4468 (1973); Hart et al., Biochemical and Biophysical Research Communication, pp. 980-986, (1978) CA 0221~046 1997-09-09 However, none of these documents describes a pharmaceutical, cosmetic or food composition comprising one of these imidazolopyrazine derivatives, or the antioxidant properties of these products, or any other S therapeutic application of these products.
Antioxidant molecules such as vitamins, for instance vitamin E (fat-soluble) or cysteine derivatives (water-soluble), are also used already in cosmetic, pharmaceutical and/or food ;applications. However, these antioxidant molecules have the drawback either of not being water-soluble, or of having an excessively high toxicity as well as an excessively low efficacy.
Objectives of the invention.
The present invention is directed towards obtaining a new pharmaceutical, cosmetic and/or food composition advantageQusly permitting the prevention and/or treatment of pathologies associated with prooxi-dant agents, and especially a pharmaceutical, cosmetic and/or food composition having anti-inflammatory and/or anticarcinogenic properties.
An additional objective of the present inven-tion is to obtain said pharmaceutical, cosmetic and/or food compositions which shall be characterized by a low toxicity or an absence of toxicity, by a high solubi-lity in a large number of solvents (H2O, alcohols, etc.)and/or lipids and/or by a high stability, especially at acid pH.
Characteristic ~eatures o~ the present invention.
The present invention relates to a pharmaceu-tical, cosmetic and/or food composition comprising apyrazine derivative of formula .B-- R 2 .~ j=<
~1 ~,~ or ~l ~ ~ ~
Nff R R ~ ~ l R4 CA 0221~046 1997-09-09 and/or its precursor of formula R3 C~2H B ~2 ~ R4 P ~
C~2--C~--~--C--C~--K~--C--C~--N~2 in which formulae B is a radical chosen from the group consisting of X, X-SO3H, X-PO4, X-alkyl=O, the said alkyl consisting of 1 to 20 carbon atoms optionally comprising 1 to 10 hetero atoms and in which the carbon atoms can be optionally substituted with any element of the Mendeleev table, preferably an element chosen from the group consisting of H, B, N, O, F, ~, S, Cl, As, Se, Br, Te and I, X being an element chosen from the group con-sisting of O, S, Se and Te;
R1, R2, R3 and R4 are H, radicals chosen from the group consisting of alkyl, alkenyl, alkynyl, aryl, aryl-alkyl, alkylaryl, heteroaryl, heteroalkyl and hetero(alkylaryl and arylalkyl), preferably con-sisting of 1 to 20 carbon atoms optionally comprising 1 to 10 hetero atoms and in which the carbon atoms can be optionally substituted with any element o~ the Mendeleev table, preferably an element chosen from the group consisting of H, B, N, O, F, P, S, Cl, As, Se, Br, Te and I, or chains of formula (Rs x R6) n, where n 2 1, x represents one or more hetero atoms and R5 and R6 are radicals chosen from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkylaryl, heteroaryl, heteroalkyl and hetero(alkylaryl and arylalkyl), consisting of 1 to 20 carbon atoms optionally comprising 1 to 10 hetero atoms and in which the carbon atoms can be optionally substituted with any element of the Mendeleev table, preferably an element chosen from the group consisting of H, B, N, O, F, P, S, Cl, As, Se, Br, Te and Ii and optionally an appropriate pharmaceutical, cosmetic and/or food vehicle.
CA 0221~046 1997-09-09 ~referably, in the pyrazine derivatives according to the invention, Rl is H, R2 and R4 are aryl or alkylaryl groups, preferably consisting of 1 to 20 carbon atoms optionally comprising 1 to 10 hetero atoms and in which the carbon atoms can be optionally substituted with any element of the Mendeleev table, preferably an element chosen from the group consisting of H, B, N, O, F, P, S, Cl, As, Se, Br, Te and I, R3 represents a phenoL group or a chain of formula (R5 X R6) n in which n = 1, x represents O, R5 iS a phenyl, and .
R6 is a methyl ~referably, the pyrazine derivative of the pharmaceutical, cosmetic and/or food composition according to the invention is chosen from the group consisting of:
* 3,7-dihydro-2-(p-hydroxybenzyl)-6-(p-hydroxyphenyl)-8-benzylimidazo[1,2-a]pyrazyn-3-one [sic] (CLZN) * 3,7-dihydro-2-methyl-6-(p-metoxyphenyl)-8-benzyl-imidazo[l,2-a]pyrazyn-3-one [sic] (CLZN-7) * 3,7-dihydro-2-phenyl-6-(p-metoxyphenyl)-8-benzyl-imidazo[l,2-a]pyrazyn-3-one [sic] (CLZN-8) * 3,7-dihydro-2-methyl-6-(p-hydroxyphenyl)-8-benzyl-imidazo[l,2-a]pyrazyn-3-one [sic] (CLZN-9) * 3,7-dihydro-2-phenyl-6-(p-hydroxyphenyl)-8-benzyl-imidazo[l,2-a]pyrazyn-3-one [sic] (CLZN-10) * 3,7-dihydro-2-benzyl-6-(p-hydroxyphenyl)-8-benzyl-imidazo[l,2-a]pyrazyn-3-one [sic] (CLZN-ll) and optionally an appropriate pharmaceutical, cosmetic and/or food vehicle.
Another aspect of the present invention relates to the use of the composition according to the invention for the binding of prooxidant agents (free radicals) such as peroxides, superoxides, etc.
The present invention also relates to a method CA 0221~046 1997-09-09 of treatment and/or prevention of pathologies associated with the action of prooxidant agents, especially inflammatory or carcinogenic pathologies, in which the pharmaceutical, cosmetic and/or food composi-tion according to the present invention is administeredto a patient.
The pharmaceutical, cosmetic and/or food vehicles according to the invention are vehicles which are appropriate, in parti~ular, for oral administra-tion, for example in the form of lozenges, coated oruncoated, pills, capsules, solutions, essential oils and/or syrups.
Other appropriate pharmaceutical, cosmetic and/or food vehicles can be used, depending on the chosen mode of administration.
In particular,_ these pharmaceutical, cosmetic and/or food vehicles can be creams or sun oils which are well known to a person skilled in the art, which can coat various parts of the human or animal body in combination with other skin-protecting agents.
In addition, the products of the invention can be readily incorporated in solvents (aqueous media, alcohols, etc.) or lipids (for example in combination with food oils or suntan oils).
The pharmaceutical, cosmetic and/or food compositions according to the invention are prepared according to processes generally used by a person skilled in the art, especially by pharmacists, and can comprise any vehicle or any adjuvant which is pharma-ceutically appropriate, solid or liquid, and non-toxic.
The incorporation of the derivatives according to the invention in a pharmaceutical formulation medium can also be envisaged.
The percentage of active product (pyrazine derivatives) in the pharmaceutical vehicle can vary over very wide ranges, limited only by the tolerance and level of acceptance of the product by the patient.
The limits are generally determined by the frequency of administra~ion to the patient.
CA 0221~046 1997-09-09 A final aspect of the present invention relates to the use of the composition according to the invention for the preparation of a medicament intended for the prevention and/or treatment of pathologies associated with the action of peroxidant agents.
In particular, the present invention relates to the use of the composition according to the invention for the preparation of a medicament intended for the prevention and/or treatment" of inflammatory or carcino-genic pathologies and/or for the treatment of cancerous tumours.
Brief description of the figures.
Figure 1 depicts the structure of the imidazolo-pyrazine derivatives used in the pharma-ceutical and food composition according to the invention.
Figure 2 depicts the relationship linking the super-oxide dismutase (SOD) concentration and the ratio of the intensities measured in the absence and in the presence of superoxide dismutase (Io/I) for two coelenterazine (CLZN) concentrations. In this figure, the results of the same experiment carried out when the superoxide dismutase is heat-denatured are also presented.
Figure 3 depicts the change in the slope of the relationship linking the superoxide dismutase concentration and Io/I and in the rate con-stant KSOD as a function of the coelenterazine concentration.
Figure 4 depicts the linear relationship between the coelenterazine concentration and the maximum intensity of the luminescence brought about by the superoxide anion under our experi-mental conditions.
Figure 5 depicts the inactivation of superoxide dismutase by 10-2 M KCN. The enzyme activity is completely inhibited by KCN, and no observable difference remains between the two CA 022l~046 l997-09-09 coelenterazine concentrations ( 10-7 and 4 10-7 M) Figure 6 depicts the influence of the luminol concen-tration on the slope of the relationship linking the superoxide dismutase concentra-tion and the ratio of the intensities Io/I.
Figure 7 depicts the stability of the derivative 10 in an aqueous medium. Three 10-5 M solutions of CLZN-10 were prepared in citrate (pH 4), phosphate (pH 7) and glycine (pH 10) buffers.
Aliquots of these solutions were sampled regularly and the CLZN-10 assayed by lumi-nescence in DMSO.
Figures 8 and 9 depict the percentage cellular survival of human fibroblasts subjected to an oxida-tive stress inducer in the presence of increasing doses of derivatives according to the invention, with (Figure 9) or without (Figure 8) serum.
Figure 10 depicts diagrammatically the conversion of a precursor of the derivative according to the invention to a derivative of the invention.
Figure 11 depicts the percentage survival of different cell types as a function of increasing doses of CLZ-9 (M).
EXAMPLES.
1. Origin of the antioxidant properties of the pharma-ceutical, cosmetic and food composition according to the invention.
The antioxidant properties of imidazolopyrazine derivatives appear to result, on the one hand from the properties of these molecules to react very rapidly with the activated forms of oxygen.
This property could be due to the existence of electron donor (carbonyl) and electron acceptor (nitro-gen) groups in the central nucleus of the molecule.
The phenol groups present in the molecules could also constitute (ROS) scavengers.
CA 022l~046 lss7-os-os The main reaction mechanism is considered to be comparable to the one involved in the chemoluminescent oxidation of coelenterazine by molecular oxygen.
On the other hand, these properties might result from the very high instability of the excited product formed during the reaction of ROSs with imidazolopyrazines.
In effect, contrary to other known substances displaying antioxidant activity, the reaction product is not a stable and unreactive radical. On the contrary, the excited product formed is considered to be characterized by a very great instability. The latter is such that these products appear to disintegrate instantaneously by rupture of the imidazolopyrazine nucleusi a part of the destructive energy of the ROSs is_dissipated in the form of light, while the remainder is liberated in the form of thermal radiation.
The results below indicate the existence of a positive cooperative interaction between the imidazolo-pyrazines and the cytosolic superoxide dismutase (Cu-Zn form) of cells.
This behaviour is demonstrated in experiments that enable the reactivity of imidazolopyrazines with the superoxide anion to be measured. This method is based on the capacity of imidazolopyrazines to react with the superoxide anion, emitting light.
In these experiments, a constant level of superoxide anion is generated by an enzymatic method, by reacting xanthine oxidase with hypoxanthine in the presence of oxygen. This reaction is carried out in the presence of increasing concentrations of superoxide dismutase (Cu-Zn superoxide dismutase), which will compete with the imidazolopyrazine for the superoxide anion and hence modify the maximum light intensity produced.
The maximum light intensity, measured by a luminometer during the competltion reaction, is linked to the ratio in [sic] imidazolopyrazine and superoxide CA 0221~046 1997-os-os _ g _ dismutase concentrations, as well as to that of the respective rate constants.
Consequently, knowing the rate constant of the reaction of the competing antioxidant with the super-oxide anion (K3), the rate constant of the reaction ofthe imidazolopyrazine with the superoxide anion (K2) may be calculated:
Io = light intensity observed in the absence of the competitor I = light intensity observed in the presence of the competitor SOD = superoxide dismutase IMPZ = imidazolopyrazine . IMPZ
~ /I = 1 +{K3 / (Kl [~2] - K2t ~ ])}[SOD] (1) 2 ~7 =' ~2 f ~, K~
IMPZ + O~ =~ . + h~ (2) - amidopyraz1ne SOD + 2 07 =~ ~7 + o 2- + SOD (3) By carrying out this experiment at two imidazolopyrazine concentrations, it is possible to eliminate K1 [o22~] corresponding to the spontaneous disproportionation reaction of o22~. The slopes A and B
of the straight lines linking Io/I [sic] to the super-oxide dismutase concentration are:
1st concentration A = K3 / (Kl [~2 ] + K2 [IMPZ]l) of IMPZ
and 2nd concentration A = K3 / (K [07] + K7 [IMPZ]l) of IMPZ
and then K~ = K3 / ( ~IMPZ]l -- [IMPZ]7) / (1 / A) -- 1 / B) CA 0221~046 1997-09-09 When the imidazolopyrazine concentration is increased, the slope of the relationship linking Io/I
[sic] to the superoxide dismutase concentration should decrease.
These experiments revealed a reverse behaviour, that is to say a rise in the slope for higher imidazolo-pyrazine concentrations (Figure 2). This demonstrates a linear relationship between the coelenterazine concen-tration and the slope of the straight line (Figure 3).
This rise in slope may be interpreted as an increase in the apparent rate constant of the superoxide dismutase.
Thus, when the coelenterazine concentration is multiplied by 8 (from 50 to 400 nM), the rate constant KSOD rises from 2 x 109 to 2.5 x 101~, equivalent to a 12.5_fold increase. This effect was observed for two other imidazolopyrazines tested (CLZN-9 and -10). The magnitude of the increase in KSOD appears to be achieved in proportions similar to those of coelenterazine.
Various controls were carried out in order to verify that the results are not due to an artefact.
These include:
- a test of linearity between the imidazolopyrazine concentration and the measured light intensity (Figure 4);
- heat denaturation of the superoxide dismutase used shows that the reduction in magnitude of light production on reacting the imidazolopyrazines with the superoxide anion does indeed result from an enzyme activity and not from the presence of metallic contaminants (Figure 2);
- the inactivation of superoxide dismutase by cyanide confirms that the enzyme activity does indeed correspond to superoxide dismutase and not to a protein contaminating the commercial sample (Figure 5);
- lastly, identical experiments were carried out with luminol, a chemoluminescent molecule that reacts with the superoxide anion, which revealed a behaviour of this product in accordance with CA 0221~046 1997-09-09 theoretical predictions, that is to say a regular decrease in the slope when the luminol concentra-tion is increased (Figure 6).
Consequently, the antioxldant and consequently anticarcinogenic properties of a pharmaceutical, cosmetic or food composition comprising imidazolo-pyrazine derivatives are completely unexpected, since the binding of superoxide dismutase by the imidazolo-pyrazine derivatives of the composition according to the invention is specific and is not observed with other chemoluminescent molecules such as luminol.
In view of the importance of superoxide dis-mutase in combating oxidative stress (see Fridovitch I, Journal of Biological Chemistry 264 (1989), pp. 7761-7764), the action of the imidazolopyrazine derivativeson this enzyme would strengthen the antioxidative defences of the cells, endowing them as a result with better protection against prooxidant agents.
2 0 2 . In vi tro toxi ci ty .
The low toxicity of the pharmaceutical, cosmetic or food composition of the invention for human cells is demonstrated in the experiments which follow.
Each of the imidazolopyrazine derivatives tested was applied to human fibroblasts (MRC5) in culture. The doses of the compounds ranged from 10-8 to 10-4 M. These compounds were applied 48 hours after the cells were inoculated into wells (volume = 150 ,ul; 3000 cells per well).
After a further 24 hour period, the culture medium is renewed, the cells are incubated for 72 hours and their level of survival and of growth is evaluated by measuring the total protein contents in each well (Biorad). The results show that the imidazolopyrazine derivatives have little or no toxicity for these cells.
Only the derivative CLZN-11 displays a significant toxicity for a concentratlon of 0.1 mM.
However, the slight toxicity of these deriva-tives at a concentration of 10-4 M is explained by the CA 0221~046 1997-09-09 negative action of the 1~ ethanol used to solubilize these derivatives. Neither of the two degradation products of the derivatives (CLMN-4 and -5) is toxic for the cells.
In comparison with coelenterazine, derivatives comprising additional phenyl groups display better stability. While the stability of coelenterazine is only a few hours in an aqueous medium and irrespective of the pH, the products derived from it display excellent stability at acid and neutral pH, while their half-life is in the region of 60 minutes at alkaline pH
(Figure 7).
Similar in vitro toxicity tests were performed on other m~mm~lian (porcine, human, etc.) cell types.
Figure 11 depicts the percentage survival of different cell types ~fibroblasts, human (ECV) or pig (EAP) endothelial cells) as a function of increasing doses of CLZ-9 (molar). A toxic effect of the products can possibly be observed on a certain cell type at high concentrations (10-4 M in pigs).
3. In vivo toxicity.
Tests showed that coelenterazine (CLZN) (at a dose of 20 ug/kg and after 5 intraperitoneal injections) is not toxic for mice (the survival is 100% and no growth retardation is observed).
Survi~al Weight (in gr~m~) a~ter 0 day 6 days 30 days Control mice 6/6 13.13 18.65 30.82 (6 males) + 1.6 + 1.75 + 1.28 Mice treated with the 5/5 16.19 22.82 31.57 comp. according to the + 1.93 + 1.82 - 1.75 inv. (5 males) CA 0221~046 1997-09-09 4, Reactivity of the compounds with activated oxygen species.
The reactivity of coelenterazine and of the derivatives of the invention with singlet oxygen was measured by pulsed photolysis. The results demonstrate the exceptional reactivity of these compounds, reaction rates reaching 2-30 x 108 M~1 S 1 These rate constants are close to the theoretical maxima, taking account of the rate of diffusion of singlet oxygen in the reaction medium, and are equal to or greater than those of most of the known antioxidant agents.
Tests showed that coelenterazine (CLZN) (at a dose of 20 ug/kg and after 5 intraperitoneal injections) is not toxic for mice (the survival is 100% and no growth retardation is observed).
Survi~al Weight (in gr~m~) a~ter 0 day 6 days 30 days Control mice 6/6 13.13 18.65 30.82 (6 males) + 1.6 + 1.75 + 1.28 Mice treated with the 5/5 16.19 22.82 31.57 comp. according to the + 1.93 + 1.82 - 1.75 inv. (5 males) CA 0221~046 1997-09-09 4, Reactivity of the compounds with activated oxygen species.
The reactivity of coelenterazine and of the derivatives of the invention with singlet oxygen was measured by pulsed photolysis. The results demonstrate the exceptional reactivity of these compounds, reaction rates reaching 2-30 x 108 M~1 S 1 These rate constants are close to the theoretical maxima, taking account of the rate of diffusion of singlet oxygen in the reaction medium, and are equal to or greater than those of most of the known antioxidant agents.
5. Antioxidant properties on fibroblasts.
Human fibroblasts were subjected to an oxida-tive stress inducer (tert-butyl hydroperoxide (t-BHP~) for 6 to 12 hours in ~he absence and in the presence of increasing doses o~ coelenterazine and its derivatives.
Cellular survival after exposure to t-BH~ (10 4 M) for 10 hours is 20 to 30%. The addition of coelenterazine and its derivatives to the incubation medium improves very significantly (* p < 0~05i ** p < 0.01) the survival o~ the t-BHP-treated cells. The attached Figures 8 and 9 present the results obtained with the compositions according to the invention.
The same experiments in which serum is also added to the medium are depicted in Figure 9.
The most advantageous results are obtained with the derivative CLZ-9. The improvement is already significant from 2 x 10 8 M, while protection is total at 10-~ M.
In the same experimental series, the efficacy of vitamin E (a-tocopherol) (Troxol~), a major anti-oxidant of animal cells, was compared. The results indicate that coelenterazine and the derivative CLZ-9 possess an antioxidant activity equivalent to (CLZN) or greater than (CLZ-9) vitamin E. These experiments were also ca~ried out in the presence of serum (10~) in the culture medium, since serum is known to reduce greatly the lire o~ antioxidants. Under these conditions, the CA 0221~046 1997-09-09 efficacy of the compounds according to the invention in protecting the cells is retained, and protection reaches 80 to 100% at the highest concentrations, while it reaches only 60% in the case of vitamin E.
Human fibroblasts were subjected to an oxida-tive stress inducer (tert-butyl hydroperoxide (t-BHP~) for 6 to 12 hours in ~he absence and in the presence of increasing doses o~ coelenterazine and its derivatives.
Cellular survival after exposure to t-BH~ (10 4 M) for 10 hours is 20 to 30%. The addition of coelenterazine and its derivatives to the incubation medium improves very significantly (* p < 0~05i ** p < 0.01) the survival o~ the t-BHP-treated cells. The attached Figures 8 and 9 present the results obtained with the compositions according to the invention.
The same experiments in which serum is also added to the medium are depicted in Figure 9.
The most advantageous results are obtained with the derivative CLZ-9. The improvement is already significant from 2 x 10 8 M, while protection is total at 10-~ M.
In the same experimental series, the efficacy of vitamin E (a-tocopherol) (Troxol~), a major anti-oxidant of animal cells, was compared. The results indicate that coelenterazine and the derivative CLZ-9 possess an antioxidant activity equivalent to (CLZN) or greater than (CLZ-9) vitamin E. These experiments were also ca~ried out in the presence of serum (10~) in the culture medium, since serum is known to reduce greatly the lire o~ antioxidants. Under these conditions, the CA 0221~046 1997-09-09 efficacy of the compounds according to the invention in protecting the cells is retained, and protection reaches 80 to 100% at the highest concentrations, while it reaches only 60% in the case of vitamin E.
6. Cosmetic composition suitable for skin hygiene.
CompositionPercentage by weight Oily phase BRIJ 721 (Stéarate 21~) buffer 4.00 Cetyl alcohol 10.00 Mineral oil 5.00 ~ropyl para-hydrobenzoate [sic]0.02 Aqueous phase Carbopol 934~ 0.10 Sodium hydroxide (10% solution)0.10 Methyl para-hydrobenzoate [sic]0.18 Derivatives according to the invention 0.05 to 5.00 Demineralized water 75.60 to 80.05 Total 100.00 The cosmetic composition according to the invention may be applied in cream form directly to the patient's skin.
The derivatives according to the invention may also be incorporated in the oily phase of the cosmetic composition instead of being dissolved in the aqueous composition.
CompositionPercentage by weight Oily phase BRIJ 721 (Stéarate 21~) buffer 4.00 Cetyl alcohol 10.00 Mineral oil 5.00 ~ropyl para-hydrobenzoate [sic]0.02 Aqueous phase Carbopol 934~ 0.10 Sodium hydroxide (10% solution)0.10 Methyl para-hydrobenzoate [sic]0.18 Derivatives according to the invention 0.05 to 5.00 Demineralized water 75.60 to 80.05 Total 100.00 The cosmetic composition according to the invention may be applied in cream form directly to the patient's skin.
The derivatives according to the invention may also be incorporated in the oily phase of the cosmetic composition instead of being dissolved in the aqueous composition.
7. Food composition according to the invention.
The composition according to the invention is added to an oily phase of a food composition, especially in spreads of the minarine or margarine type.
CA 022l~046 l997-09-09 Composition Percentage by weight Oily phase Butter 12.50 Mixture of oils which has incorporated 10.00 derivatives according to the invention Monoglycerides 0.47 Lecithin 0.20 ~-Carotene (30% in oil) 0-03 A~ueous pha~e Water 59~70 Sugar or sugar substitute 0.15 Gelatin - 1.5 Salt 0 5 Potassium sorbate 0.10 Lactic acid < 0.10 Method of production Oily phase : the powdered ingredients are incorporated in the mixture of oils, to which melted butter and, where appropriate, a colorant are added. This fatty phase is stored at 55~C.
Aqueous phase : the gelatin is dispersed in water at 80~C, the other ingredients are added and the pH is adjusted to 5 with lactic acid. The ingredients are mixed until a homogeneous mass is obtained, and the aqueous mixture is stored at 55~C.
The aqueous phase is then incorporated slowly and with vigorous stirring in the fatty dispersion at 55~C. The product is then homogenized at 200 bars and then allowed to cool rapidly to 12~C. The product is packaged in cartons and stored refrigerated before administration to a patient.
CA 0221~046 1997-09-09 Other examples of cosmetic or food compositions can comprise the compounds according to the invention in combination with other adjuvants, which can be incorporated in the aqueous phase or the oily phase of the cosmetic and/or food compositions according to the invention.
The inventors have also depicted, in Figure 10, the conversion of a precursor of a derivative according to the invention to a pyra~ine derivative.
As is seen in Figure 10, the precursor of the invention is capable of also binding free radicals so as to obtain the derivative according to the invention, which is still active and also capable of binding free radicals.
Unexpectedly, the Applicant also observed that the derivatives of the invention possess antitumour properties, especially with respect to mammary carcinoma at low concentrations.
Hence the derivatives of the invention have a lethal effect on cancer cell lines at concentrations at which they are not toxic for normal cells.
The composition according to the invention is added to an oily phase of a food composition, especially in spreads of the minarine or margarine type.
CA 022l~046 l997-09-09 Composition Percentage by weight Oily phase Butter 12.50 Mixture of oils which has incorporated 10.00 derivatives according to the invention Monoglycerides 0.47 Lecithin 0.20 ~-Carotene (30% in oil) 0-03 A~ueous pha~e Water 59~70 Sugar or sugar substitute 0.15 Gelatin - 1.5 Salt 0 5 Potassium sorbate 0.10 Lactic acid < 0.10 Method of production Oily phase : the powdered ingredients are incorporated in the mixture of oils, to which melted butter and, where appropriate, a colorant are added. This fatty phase is stored at 55~C.
Aqueous phase : the gelatin is dispersed in water at 80~C, the other ingredients are added and the pH is adjusted to 5 with lactic acid. The ingredients are mixed until a homogeneous mass is obtained, and the aqueous mixture is stored at 55~C.
The aqueous phase is then incorporated slowly and with vigorous stirring in the fatty dispersion at 55~C. The product is then homogenized at 200 bars and then allowed to cool rapidly to 12~C. The product is packaged in cartons and stored refrigerated before administration to a patient.
CA 0221~046 1997-09-09 Other examples of cosmetic or food compositions can comprise the compounds according to the invention in combination with other adjuvants, which can be incorporated in the aqueous phase or the oily phase of the cosmetic and/or food compositions according to the invention.
The inventors have also depicted, in Figure 10, the conversion of a precursor of a derivative according to the invention to a pyra~ine derivative.
As is seen in Figure 10, the precursor of the invention is capable of also binding free radicals so as to obtain the derivative according to the invention, which is still active and also capable of binding free radicals.
Unexpectedly, the Applicant also observed that the derivatives of the invention possess antitumour properties, especially with respect to mammary carcinoma at low concentrations.
Hence the derivatives of the invention have a lethal effect on cancer cell lines at concentrations at which they are not toxic for normal cells.
Claims (8)
1. Pharmaceutical, cosmetic and/or food composition comprising a pyrazine derivative of formula or and/or its precursor of formula characterized in that B is a radical chosen from the group consisting of x, X-SO3H, X-PO4 and X-alkyl=O in which X is an element chosen from the group consisting of O, S, Se and Te, R1, R2, R3 and R4 are H, radicals chosen from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkylaryl, heteroaryl, heteroalkyl and hetero(alkylaryl and arylalkyl), optionally substituted, or chains of formula (R5 x R6)n, where n ~ 1, x represents one or more hetero atoms and R5 and R6 are radicals chosen from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkylaryl, heteroaryl, heteroalkyl and hetero(alkylaryl and arylalkyl), optionally substituted and an appropriate pharmaceutical, cosmetic and/or food vehicle.
2. Pharmaceutical, cosmetic and/or food composition according to Claim 1, characterized in that R1 is H, R2 and R4 are aryl or alkylaryl groups, optionally substituted, R3 represents a phenol group or a chain of formula (R5 x R6)n in which n=1, x represents O, R5 is a phenyl and R6 is a methyl.
3. Pharmaceutical, cosmetic and/or food composition according to any one of the preceding claims, comprising a pyrazine derivative chosen from the group consisting of:
* 3,7-dihydro-2-(p-hydroxybenzyl)-6-(p-hydroxyphenyl)-8-benzylimidazo[1,2-a]pyrazyn-3-one [sic]
* 3,7-dihydro-2-methyl-6-(p-metoxyphenyl)-8-benzyl-imidazo[1,2-a]pyrazyn-3-one [sic]
* 3,7-dihydro-2-phenyl]-6-(p-metoxyphenyl)-8-benzyl-imidazo[1,2-a]pyrazyn-3-one [sic]
* 3,7-dihydro-2-methyl-6-(p-hydroxyphenyl)-8-benzyl-imidazo[1,2-a]pyrazyn-3-one [sic]
* 3,7-dihydro-2-phenyl-6-(p-hydroxyphenyl)-8-benzyl-imidazo[1,2-a]pyrazyn-3-one [sic]
* 3,7-dihydro-2-benzyl-6-(p-hydroxyphenyl)-8-benzyl-imidazo[1,2-a]pyrazyn-3-one [sic]
* 3,7-dihydro-2-(p-hydroxybenzyl)-6-(p-hydroxyphenyl)-8-benzylimidazo[1,2-a]pyrazyn-3-one [sic]
* 3,7-dihydro-2-methyl-6-(p-metoxyphenyl)-8-benzyl-imidazo[1,2-a]pyrazyn-3-one [sic]
* 3,7-dihydro-2-phenyl]-6-(p-metoxyphenyl)-8-benzyl-imidazo[1,2-a]pyrazyn-3-one [sic]
* 3,7-dihydro-2-methyl-6-(p-hydroxyphenyl)-8-benzyl-imidazo[1,2-a]pyrazyn-3-one [sic]
* 3,7-dihydro-2-phenyl-6-(p-hydroxyphenyl)-8-benzyl-imidazo[1,2-a]pyrazyn-3-one [sic]
* 3,7-dihydro-2-benzyl-6-(p-hydroxyphenyl)-8-benzyl-imidazo[1,2-a]pyrazyn-3-one [sic]
4. Use of the pharmaceutical, cosmetic and/or food composition according to any one of the preceding claims, for the binding of prooxidant agents.
5. Use of the pharmaceutical composition according to any one of Claims 1 to 3, for the preparation of a medicament intended for the prevention and/or treatment of pathologies associated with the action of prooxidant agents.
6. Use of the pharmaceutical composition according to any one of Claims 1 to 3, for the preparation of a medicament intended for the prevention and/or treatment of inflammatory pathologies.
7. Use of the pharmaceutical composition according to any one of Claims 1 to 3, for the preparation of a medicament intended for the prevention and/or treatment of carcinogenic pathologies.
8. Use of the pharmaceutical composition according to any one of Claims 1 to 3, for the preparation of a medicament intended for the treatment of cancerous tumours.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE9500207A BE1009196A3 (en) | 1995-03-09 | 1995-03-09 | Pharmaceutical composition, cosmetic and / or food to properties antioxidant. |
BE9500207 | 1995-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2215046A1 true CA2215046A1 (en) | 1996-09-19 |
Family
ID=3888837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002215046A Abandoned CA2215046A1 (en) | 1995-03-09 | 1996-03-11 | Pharmaceutical, cosmetic and/or food composition having anti-oxidant properties |
Country Status (6)
Country | Link |
---|---|
US (1) | US6204266B1 (en) |
EP (1) | EP0814808A1 (en) |
JP (1) | JPH11501633A (en) |
BE (1) | BE1009196A3 (en) |
CA (1) | CA2215046A1 (en) |
WO (1) | WO1996028160A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376498B1 (en) | 1997-03-28 | 2002-04-23 | Universite Catholique De Louvain | Pharmaceutical, cosmetic and/or food composition with antioxidant properties |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1292580A1 (en) * | 2000-05-17 | 2003-03-19 | Universite Catholique De Louvain | Pyrazine and imidazopyrazine derivatives as antioxidants |
TW200800213A (en) | 2005-09-02 | 2008-01-01 | Abbott Lab | Novel imidazo based heterocycles |
WO2012127441A1 (en) * | 2011-03-23 | 2012-09-27 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK487784A (en) * | 1983-10-13 | 1985-04-14 | Univ Georgia | IMMUNOASSAY |
JPS62261942A (en) * | 1986-05-08 | 1987-11-14 | Chisso Corp | Detection of metal |
JPS6447379A (en) * | 1987-08-19 | 1989-02-21 | Chisso Corp | Preparation of calcium-dependent oxygenation enzyme |
-
1995
- 1995-03-09 BE BE9500207A patent/BE1009196A3/en not_active IP Right Cessation
-
1996
- 1996-03-11 CA CA002215046A patent/CA2215046A1/en not_active Abandoned
- 1996-03-11 WO PCT/BE1996/000024 patent/WO1996028160A1/en not_active Application Discontinuation
- 1996-03-11 US US08/930,439 patent/US6204266B1/en not_active Expired - Fee Related
- 1996-03-11 EP EP96905618A patent/EP0814808A1/en not_active Withdrawn
- 1996-03-11 JP JP8527122A patent/JPH11501633A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376498B1 (en) | 1997-03-28 | 2002-04-23 | Universite Catholique De Louvain | Pharmaceutical, cosmetic and/or food composition with antioxidant properties |
Also Published As
Publication number | Publication date |
---|---|
JPH11501633A (en) | 1999-02-09 |
EP0814808A1 (en) | 1998-01-07 |
US6204266B1 (en) | 2001-03-20 |
BE1009196A3 (en) | 1996-12-03 |
WO1996028160A1 (en) | 1996-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Moslen | Reactive oxygen species in normal physiology, cell injury and phagocytosis | |
Fridovich | Oxygen is toxic! | |
Ernster et al. | Biochemical, physiological and medical aspects of ubiquinone function | |
EP1386905B1 (en) | Stable solution of reduced coenzyme q | |
US5633285A (en) | Cytoprotective wound healing compositions and methods for preparing and using same | |
EP0652010A1 (en) | Use of alphatocopherol acetate or a derivative for the preparation of cosmetic, dermatalogical or pharmaceutical compositions with anti radical activity | |
EP0614359A1 (en) | Wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids | |
KR20060100402A (en) | Composition containing reduced coenzyme q | |
TWI245628B (en) | Stabilized composition of reduced coenzyme Q10 aqueous solution | |
Sepe et al. | Oxidant membrane injury by the neutrophil myeloperoxidase system. II. Injury by stimulated neutrophils and protection by lipid-soluble antioxidants. | |
JPS63218649A (en) | Antioxidant amino acid base substance and antioxidant | |
EP0627917A1 (en) | Cytoprotective compositions containing pyruvate and antioxidants | |
JP4401617B2 (en) | Cucumismelo extract coated and / or microencapsulated in a fat-soluble agent based on fatty substances | |
US20050181021A1 (en) | Vitamin E phosphate/phosphatidycholine liposomes to protect from or ameliorate cell damage | |
Öztürk et al. | Antimicrobial and biological effects of ipemphos and amphos on bacterial and yeast strains | |
NL193398C (en) | Antioxidant oil composition and method for its preparation. | |
US6204266B1 (en) | Pharmaceutical, cosmetic and/or food composition having anti-oxidant properties | |
Brigelius-Flohé et al. | Selenium: an antioxidant? | |
Kitabchi et al. | Adrenal Gland in Vitamin E Deficiency: III. INHIBITION OF ADRENOCORTICOTROPIC HORMONE-INDUCED STEROIDOGENESIS IN ISOLATED ADRENAL CELLS BY ASCORBIC ACID | |
Mukhopadhyay et al. | Vitamin D3 as a modulator of cellular antioxidant defence in murine lymphoma | |
WO2002081027A1 (en) | An antioxidant composition and a cosmetic or pharmaceutical composition | |
US6376498B1 (en) | Pharmaceutical, cosmetic and/or food composition with antioxidant properties | |
CN105473139B (en) | For effectively treating, preventing or improve the chlorin e 6 of acne | |
JPH06107539A (en) | Tyrosinase inhibitor | |
CA1162564A (en) | Skin-beautifying cosmetic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20040311 |